Condition: Primary Biliary Cirrhosis · Sponsor: University of Aarhus
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.
This description comes directly from the study's public registry record.
Henning Grønbæk, Prof, MD · +45 21679281 · henngroe@rm.dk
Lars Bossen, MD · +45 22800676 · larsbossen@clin.au.dk
Always discuss trial participation with your own doctor first.
| Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark | Aarhus N, Central Jutland, Denmark | Recruiting |
| Department of Medicine, Gastrounit Medical division | Hvidovre, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04514965